Christopher John Morl is Chief Business Officer at Deciphera Pharmaceuticals, Inc. (DCPH). They have made 6 open-market trades across 1 company since 2019, most recently 2020-01-16.
CIK 0001716821
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| DCPH | 12,023 | $308K |
Shares reported on the most recent Form 4, priced at the 2020-01-17 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| DCPH | SELL | 2020-01-15 | 2020-01-17 | $65.26 | $2.0M | -7.5% | -20.5% | -37.1% |
| DCPH | SELL | 2020-01-07 | 2020-01-09 | $60.11 | $1.6M | +6.1% | +10.3% | -29.1% |
| DCPH | SELL | 2020-01-02 | 2020-01-06 | $58.37 | $1.8M | +17.6% | +17.6% | -26.1% |
| DCPH | SELL | 2019-12-12 | 2019-12-13 | $60.00 | $902K | +4.0% | -4.3% | -39.4% |
| DCPH | SELL | 2019-12-09 | 2019-12-11 | $55.00 | $827K | +16.8% | +7.1% | -14.4% |
| DCPH | SELL | 2019-12-03 | 2019-12-05 | $50.00 | $752K | +35.1% | +10.8% | +11.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.